#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Dementia with Lewy bodies Giant cell tumour of tendon sheath Pulmonary fibrosis Cerebral arteriovenous malformation haemorrhagic Chronic granulomatous disease Hepatitis D Ornithine transcarbamoylase deficiency Biliary neoplasm Meningitis meningococcal B-cell lymphoma recurrent Transient ischaemic attack Inflammatory myofibroblastic tumour Hypereosinophilic syndrome Anaplastic large cell lymphoma T- and null-cell types Pericarditis More trials…

    Learn about Rare Diseases

    Urea cycle disorder Pelizaeus-Merzbacher disease – Basic Information Nephrotic syndrome – Diagnostics Undifferentiated sarcoma – Diagnostics Urea cycle disorder – Trials in Disease Kearns-Sayre syndrome – Treatment Testicular leiomyosarcoma – Trials in Disease Mast cell activation syndrome Stevens-Johnson syndrome – Trials in Disease Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    FIBRIN Dextran 70 Cisatracurium Besilate ABY-271 Pentixather YOHIMBINE HYDROCHLORIDE Caspofungin Acetate Dexchlorpheniramine Maleate Urapidil ADMILPARANT Lovastatin D5-Ethyl-Beta-D-Glucuronide ANUMIGILIMAB A/(H3N2)-LIKE VIRUS ANTIGEN Candesartan Cilexetil Tavapadon Albumin Teriflunomide SRSD107 Tofacitinib Citrate More therapies…

    Learn about Your Condition

    Cartilage injury Fallopian tube cancer stage IV Alcoholic liver disease Congenital aplastic anaemia Essential hypertension Aplastic anaemia Metastasis Andersen-Tawil syndrome Dengue fever Ovarian granulosa cell tumour Eosinophilic oesophagitis Peritonitis Diabetic gastroparesis Skin angiosarcoma Testicular germ cell tumour More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Istituto Oncologico Veneto

Istituto Oncologico Veneto

Via Gattamelata 64, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Pegfilgrastim
    • Capecitabine
    • Carboplatin
    Austria France Germany Greece Italy Poland +4

  • Study of toripalimab, cisplatin and gemcitabine combination as first treatment for patients with recurrent or metastatic nasopharyngeal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Nasopharyngeal cancer
    Investigated Drugs:
    • Toripalimab
    • Cisplatin
    • Gemcitabine
    Italy

  • Study of pembrolizumab and lenvatinib treatment for patients with vulvar cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Lenvatinib
    • Pembrolizumab
    Italy

  • Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Cyclophosphamide
    Belgium Czechia Finland France Germany Greece +8

  • Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

    Recruiting

    2 1 1
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    France Germany Italy Poland Romania Spain +1

  • Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

    Recruiting

    4 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Czechia France Germany Greece +5

  • Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Epirubicin
    • Leuprorelin Acetate
    • Anastrozole
    Belgium France Greece Ireland Italy Poland +1

  • Study of ONO-4578 and nivolumab with drug combination for first-line treatment in patients with PD-L1 positive advanced colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • 4-[4-CYANO-2-[[(1’R,4S)-6-(PROPAN-2-YLCARBAMOYL)SPIRO[2,3-DIHYDROCHROMENE-4,2′-CYCLOPROPANE]-1′-CARBONYL]AMINO]PHENYL]BUTANOIC ACID
    • Bevacizumab
    • Calcium Folinate
    France Italy Spain

  • Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    • Bevacizumab
    • Capecitabine
    France Germany Italy Spain

  • Study of lurbinectedin and irinotecan in adults and young adults with advanced desmoplastic small round cell tumor

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Desmoplastic small round cell tumour
    Investigated Drugs:
    • Lurbinectedin
    • Irinotecan Hydrochloride Trihydrate
    Italy Spain
Previous Page
1 … 4 5 6 7 8 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!